Nona Biosciences (Suzhou) Co., Ltd, a wholly-owned subsidiary of HBM Holdings Ltd., has entered into a non-exclusive license agreement with Pfizer. Under this agreement, Pfizer will have global rights to access Nona Biosciences' proprietary HCAb platform to generate fully human heavy chain-only antibodies. Nona Biosciences will receive an upfront payment and is eligible for milestone payments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on November 19, 2025, and is solely responsible for the information contained therein.